Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Jan;35(1):30–34. doi: 10.1111/j.1365-2125.1993.tb05666.x

Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.

D Wu 1, S V Otton 1, B A Sproule 1, U Busto 1, T Inaba 1, W Kalow 1, E M Sellers 1
PMCID: PMC1381486  PMID: 8448065

Abstract

1. In microsomes prepared from three human livers, methadone competitively inhibited the O-demethylation of dextromethorphan, a marker substrate for CYP2D6. The apparent Ki value of methadone ranged from 2.5 to 5 microM. 2. Two hundred and fifty-two (252) white Caucasians, including 210 unrelated healthy volunteers and 42 opiate abusers undergoing treatment with methadone were phenotyped using dextromethorphan as the marker drug. Although the frequency of poor metabolizers was similar in both groups, the extensive metabolizers among the opiate abusers tended to have higher O-demethylation metabolic ratios and to excrete less of the dose as dextromethorphan metabolites than control extensive metabolizer subjects. These data suggest inhibition of CYP2D6 by methadone in vivo as well. 3. Because methadone is widely used in the treatment of opiate abuse, inhibition of CYP2D6 activity in these patients might contribute to exaggerated response or unexpected toxicity from drugs that are substrates of this enzyme.

Full text

PDF
30

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beckett A. H., Taylor J. F., Casy A. F., Hassan M. M. The biotransformation of methadone in man: synthesis and identification of a major metabolite. J Pharm Pharmacol. 1968 Oct;20(10):754–762. doi: 10.1111/j.2042-7158.1968.tb09634.x. [DOI] [PubMed] [Google Scholar]
  2. Bell J., Bowron P., Lewis J., Batey R. Serum levels of methadone in maintenance clients who persist in illicit drug use. Br J Addict. 1990 Dec;85(12):1599–1602. doi: 10.1111/j.1360-0443.1990.tb01648.x. [DOI] [PubMed] [Google Scholar]
  3. Boobis A. R., Murray S., Kahn G. C., Robertz G. M., Davies D. S. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol. 1983 Mar;23(2):474–481. [PubMed] [Google Scholar]
  4. Brøsen K., Gram L. F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol. 1989;36(6):537–547. doi: 10.1007/BF00637732. [DOI] [PubMed] [Google Scholar]
  5. Campbell M. E., Grant D. M., Inaba T., Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos. 1987 Mar-Apr;15(2):237–249. [PubMed] [Google Scholar]
  6. Chen Z. R., Somogyi A. A., Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit. 1990 Jan;12(1):97–104. doi: 10.1097/00007691-199001000-00018. [DOI] [PubMed] [Google Scholar]
  7. Dayer P., Desmeules J., Leemann T., Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun. 1988 Apr 15;152(1):411–416. doi: 10.1016/s0006-291x(88)80729-0. [DOI] [PubMed] [Google Scholar]
  8. Dayer P., Leemann T., Striberni R. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity. Clin Pharmacol Ther. 1989 Jan;45(1):34–40. doi: 10.1038/clpt.1989.6. [DOI] [PubMed] [Google Scholar]
  9. Desmeules J., Gascon M. P., Dayer P., Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol. 1991;41(1):23–26. doi: 10.1007/BF00280101. [DOI] [PubMed] [Google Scholar]
  10. Eichelbaum M., Gross A. S. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. Pharmacol Ther. 1990;46(3):377–394. doi: 10.1016/0163-7258(90)90025-w. [DOI] [PubMed] [Google Scholar]
  11. Faccini G. B., Puchetti V., Zatti N. Dextromethorphan oxidation phenotypes as markers for susceptibility to lung cancer. Clin Chem. 1990 Feb;36(2):387–387. [PubMed] [Google Scholar]
  12. Fonne-Pfister R., Bargetzi M. J., Meyer U. A. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun. 1987 Nov 13;148(3):1144–1150. doi: 10.1016/s0006-291x(87)80252-8. [DOI] [PubMed] [Google Scholar]
  13. Fonne-Pfister R., Meyer U. A. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol. 1988 Oct 15;37(20):3829–3835. doi: 10.1016/0006-2952(88)90063-9. [DOI] [PubMed] [Google Scholar]
  14. Gonzalez F. J., Meyer U. A. Molecular genetics of the debrisoquin-sparteine polymorphism. Clin Pharmacol Ther. 1991 Sep;50(3):233–238. doi: 10.1038/clpt.1991.131. [DOI] [PubMed] [Google Scholar]
  15. Henthorn T. K., Spina E., Dumont E., von Bahr C. In vitro inhibition of a polymorphic human liver P-450 isozyme by narcotic analgesics. Anesthesiology. 1989 Feb;70(2):339–342. doi: 10.1097/00000542-198902000-00025. [DOI] [PubMed] [Google Scholar]
  16. Inaba T., Jurima M., Mahon W. A., Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos. 1985 Jul-Aug;13(4):443–448. [PubMed] [Google Scholar]
  17. Inaba T., Tyndale R. E., Mahon W. A. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. Br J Clin Pharmacol. 1986 Aug;22(2):199–200. doi: 10.1111/j.1365-2125.1986.tb05251.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Inturrisi C. E., Colburn W. A., Kaiko R. F., Houde R. W., Foley K. M. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther. 1987 Apr;41(4):392–401. doi: 10.1038/clpt.1987.47. [DOI] [PubMed] [Google Scholar]
  19. Inturrisi C. E., Verebely K. The levels of methadone in the plasma in methadone maintenance. Clin Pharmacol Ther. 1972 Sep-Oct;13(5):633–637. doi: 10.1002/cpt1972135part1633. [DOI] [PubMed] [Google Scholar]
  20. Kitchen I., Tremblay J., André J., Dring L. G., Idle J. R., Smith R. L., Williams R. T. Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica. 1979 Jul;9(7):397–404. doi: 10.3109/00498257909038744. [DOI] [PubMed] [Google Scholar]
  21. Kolar A. F., Brown B. S., Weddington W. W., Ball J. C. A treatment crisis: cocaine use by clients in methadone maintenance programs. J Subst Abuse Treat. 1990;7(2):101–107. doi: 10.1016/0740-5472(90)90005-b. [DOI] [PubMed] [Google Scholar]
  22. Kosten T. R., Gawin F. H., Morgan C., Nelson J. C., Jatlow P. Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse. 1990;16(3-4):329–336. doi: 10.3109/00952999009001594. [DOI] [PubMed] [Google Scholar]
  23. Larrey D., Amouyal G., Tinel M., Letteron P., Berson A., Labbe G., Pessayre D. Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol. 1987 Nov;24(5):676–679. doi: 10.1111/j.1365-2125.1987.tb03230.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Leemann T., Dayer P., Meyer U. A. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol. 1986;29(6):739–741. doi: 10.1007/BF00615971. [DOI] [PubMed] [Google Scholar]
  25. Lennard M. S. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. Pharmacol Toxicol. 1990 Oct;67(4):273–283. doi: 10.1111/j.1600-0773.1990.tb00830.x. [DOI] [PubMed] [Google Scholar]
  26. Maany I., Dhopesh V., Arndt I. O., Burke W., Woody G., O'Brien C. P. Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry. 1989 Dec;146(12):1611–1613. doi: 10.1176/ajp.146.12.1611. [DOI] [PubMed] [Google Scholar]
  27. Meyer U. A., Skoda R. C., Zanger U. M. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. Pharmacol Ther. 1990;46(2):297–308. doi: 10.1016/0163-7258(90)90096-k. [DOI] [PubMed] [Google Scholar]
  28. Mikus G., Somogyi A. A., Bochner F., Eichelbaum M. Codeine O-demethylation: rat strain differences and the effects of inhibitors. Biochem Pharmacol. 1991 Mar 1;41(5):757–762. doi: 10.1016/0006-2952(91)90077-i. [DOI] [PubMed] [Google Scholar]
  29. Mortimer O., Persson K., Ladona M. G., Spalding D., Zanger U. M., Meyer U. A., Rane A. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin Pharmacol Ther. 1990 Jan;47(1):27–35. doi: 10.1038/clpt.1990.4. [DOI] [PubMed] [Google Scholar]
  30. Nebert D. W., Nelson D. R., Coon M. J., Estabrook R. W., Feyereisen R., Fujii-Kuriyama Y., Gonzalez F. J., Guengerich F. P., Gunsalus I. C., Johnson E. F. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 1991 Jan-Feb;10(1):1–14. doi: 10.1089/dna.1991.10.1. [DOI] [PubMed] [Google Scholar]
  31. Nielsen M. D., Brøsen K., Gram L. F. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br J Clin Pharmacol. 1990 Mar;29(3):299–304. doi: 10.1111/j.1365-2125.1990.tb03639.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Otton S. V., Inaba T., Kalow W. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci. 1984 Jan 2;34(1):73–80. doi: 10.1016/0024-3205(84)90332-1. [DOI] [PubMed] [Google Scholar]
  33. Otton S. V., Inaba T., Kalow W. Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sci. 1983 Feb 14;32(7):795–800. doi: 10.1016/0024-3205(83)90315-6. [DOI] [PubMed] [Google Scholar]
  34. Pohland A., Boaz H. E., Sullivan H. R. Synthesis and identification of metabolites resulting from the biotransformation of DL-methadone in man and in the rat. J Med Chem. 1971 Mar;14(3):194–197. doi: 10.1021/jm00285a004. [DOI] [PubMed] [Google Scholar]
  35. Schmid B., Bircher J., Preisig R., Küpfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther. 1985 Dec;38(6):618–624. doi: 10.1038/clpt.1985.235. [DOI] [PubMed] [Google Scholar]
  36. Spina E., Koike Y. Differential effects of cimetidine and ranitidine on imipramine demethylation and desmethylimipramine hydroxylation by human liver microsomes. Eur J Clin Pharmacol. 1986;30(2):239–242. doi: 10.1007/BF00614311. [DOI] [PubMed] [Google Scholar]
  37. Tyndale R. F., Inaba T., Kalow W. Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro. Drug Metab Dispos. 1989 May-Jun;17(3):334–340. [PubMed] [Google Scholar]
  38. Yue Q. Y., Svensson J. O., Alm C., Sjöqvist F., Säwe J. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol. 1989 Dec;28(6):639–645. doi: 10.1111/j.1365-2125.1989.tb03556.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES